🚀 VC round data is live in beta, check it out!

CSL Valuation Multiples

Discover revenue and EBITDA valuation multiples for CSL and similar public comparables like Jiangsu Hengrui Pharma, Lonza Group, argenx, Bayer and more.

Start Free TrialSee companies similar to CSL

CSL Overview

About CSL

CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

Founded

1991

HQ

Australia

Employees

29.0K

Website

csl.com

Financials (LTM)

Revenue: $16B
EBITDA: $5B

EV

$60B

Valuation Multiples

Multiples.vc

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CSL Financials

CSL reported last 12-month revenue of $16B and EBITDA of $5B.

In the same LTM period, CSL generated $9B in gross profit, $5B in EBITDA, and $3B in net income.

Revenue (LTM)

CSL P&L

In the most recent fiscal year, CSL reported revenue of $16B and EBITDA of $5B.

CSL expects next 12-month revenue of XXX and NTM EBITDA of XXX

See CSL forward-looking valuation multiples
LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue$16BXXX$16BXXXXXXXXX
Gross Profit$9BXXX$8BXXXXXXXXX
Gross Margin55%XXX51%XXXXXXXXX
EBITDA$5BXXX$5BXXXXXXXXX
EBITDA Margin34%XXX33%XXXXXXXXX
EBIT Margin30%XXX28%XXXXXXXXX
Net Profit$3BXXX$3BXXXXXXXXX
Net Margin21%XXX21%XXXXXXXXX
Net Debt——$8BXXXXXXXXX

Financial data powered by Morningstar, Inc.

CSL Stock Performance

CSL has current market cap of $50B, and enterprise value of $60B.

Market Cap Evolution

CSL's stock price is $103.20.

See CSL trading valuation data
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$60B$50B0.0%XXXXXXXXX$6.64

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CSL Valuation Multiples

CSL trades at 3.8x EV/Revenue multiple, and 11.2x EV/EBITDA.

See valuation multiples for CSL and 15K+ public comps

EV / Revenue (LTM)

CSL Financial Valuation Multiples

As of March 25, 2026, CSL has market cap of $50B and EV of $60B.

Equity research analysts estimate CSL's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CSL has a P/E ratio of 15.0x.

LTMNTMLast FYFY 2026FY 2027FY 2028
Market cap (current)$50BXXX$50BXXXXXXXXX
EV (current)$60BXXX$60BXXXXXXXXX
EV/Revenue3.8xXXX3.9xXXXXXXXXX
EV/EBITDA11.2xXXX11.6xXXXXXXXXX
EV/EBIT12.8xXXX13.6xXXXXXXXXX
EV/Gross Profit6.9xXXX7.5xXXXXXXXXX
P/E15.0xXXX15.6xXXXXXXXXX
EV/FCF20.5xXXX20.2xXXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CSL Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CSL Margins & Growth Rates

CSL's revenue in the last 12 month grew by 3%.

CSL's revenue per employee in the last FY averaged $0.5M.

CSL's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CSL's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for CSL and other 15K+ public comps

CSL Operational Valuation Multiples

LTMNTMLast FYFY 2026FY 2027FY 2028
Revenue Growth3%XXX2%XXXXXXXXX
EBITDA Margin34%XXX33%XXXXXXXXX
EBITDA Growth6%XXX5%XXXXXXXXX
Rule of 40—XXX38%XXXXXXXXX
Bessemer Rule of X—XXX43%XXXXXXXXX
Revenue per Employee—XXX$0.5MXXXXXXXXX
S&M Expenses to Revenue10%XXX10%XXXXXXXXX
G&A Expenses to Revenue6%XXX6%XXXXXXXXX
R&D Expenses to Revenue8%XXX9%XXXXXXXXX
Opex to Revenue—XXX32%XXXXXXXXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

CSL Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

EV/RevenueEV/EBITDA
LTM2026E2027ELTM2026E2027E
Jiangsu Hengrui PharmaXXXXXXXXXXXXXXXXXX
Lonza GroupXXXXXXXXXXXXXXXXXX
argenxXXXXXXXXXXXXXXXXXX
BayerXXXXXXXXXXXXXXXXXX
ZoetisXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXX

Valuation data powered by FactSet, Inc.

CSL M&A Activity

CSL acquired XXX companies to date.

Last acquisition by CSL was on XXXXXXXX, XXXXX. CSL acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See M&A valuation multiples

Latest Acquisitions by CSL

Acquired CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.

Start Free Trial

CSL Investment Activity

CSL invested in XXX companies to date.

CSL made its latest investment on XXXXXXXX, XXXXX. CSL invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).

See VC round multiples

Latest Investments by CSL

CompanyValuationEV/RevenueEV/EBITDA
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXX

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CSL

When was CSL founded?CSL was founded in 1991.
Where is CSL headquartered?CSL is headquartered in Australia.
How many employees does CSL have?As of today, CSL has over 29K employees.
Who is the CEO of CSL?CSL's CEO is Paul McKenzie.
Is CSL publicly listed?Yes, CSL is a public company listed on Australian Securities Exchange.
What is the stock symbol of CSL?CSL trades under CSL ticker.
When did CSL go public?CSL went public in 1994.
Who are competitors of CSL?CSL main competitors are Jiangsu Hengrui Pharma, Lonza Group, argenx, Bayer.
What is the current market cap of CSL?CSL's current market cap is $50B.
What is the current revenue of CSL?CSL's last 12 months revenue is $16B.
What is the current revenue growth of CSL?CSL revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of CSL?Current revenue multiple of CSL is 3.8x.
Is CSL profitable?Yes, CSL is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of CSL?CSL's last 12 months EBITDA is $5B.
What is CSL's EBITDA margin?CSL's last 12 months EBITDA margin is 34%.
What is the current EV/EBITDA multiple of CSL?Current EBITDA multiple of CSL is 11.2x.
What is the current FCF of CSL?CSL's last 12 months FCF is $3B.
What is CSL's FCF margin?CSL's last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of CSL?Current FCF multiple of CSL is 20.5x.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial